Cancer Chemotherapy and Pharmacology

, Volume 32, Issue 5, pp 373–378 | Cite as

Human autopsy-tissue distribution of menogaril and its metabolites

  • David J. Stewart
  • Darshan Grewaal
  • Robert M. Green
  • Rakesh Goel
  • Nadia Mikhael
  • Vital A. J. Montpetit
  • Deidre Redmond
  • Robert Earhart
Original Articles Menogaril, Tissue Concentration, Human

Abstract

Autopsy-tissues were obtained from eight patients who had last received menogaril (total cumulative dose, 175–1080 mg/m2) intravenously (one patient) or orally (seven patients) from 1 to 285 days prior to death. Tissue samples were assayed for menogaril and its metabolities by high-pressure liquid chromatography. Unchanged menogaril was found only in a single lung-tissue sample from a patient who had died < 24 h after receiving his last treatment.N-Demethylmenogaril was found in two lung-tissue samples and in single samples of the thyroid, lymph node, pancreas, cerebellum, and tumor. The major menogaril metabolite found in human autopsy-tissues was 7-deoxynogarol. The highest 7-deoxynogarol concentrations were found in the large bowel (median, 201 ng/g), liver (median, 183 ng/g), and lung (median, 177 ng/g). The heart ranked as the 9th of 18 organs in median 7-deoxynogarol concentration, after the large bowel, liver, lung, tumor, thyroid, skeletal muscle, adrenal gland, and kidney. The lowest concentrations were detected in brain tissue. Our results suggest that the low degree of cardiac toxicity and the possible pulmonary toxicity of menogaril may be related to relative tissue concentrations of menogaril metabolites. Tumor 7-deoxynogarol concentrations were comparable with those in normal tissues, except that concentrations in intracerebral tumors were higher than those in the normal brain. Tissue 7-deoxynogarol concentrations appeared to be directly related to the cumulative dose and inversely related to the time from the last treatment to death; the value obtained by dividing dose by time correlated (P<0.05) with tissue 7-deoxynogarol concentrations.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Bischoff KB (1975) Some fundamental considerations of the application of pharmacokinetics to cancer chemotherapy. Cancer Chemother Rep 59: 777–793Google Scholar
  2. 2.
    Cummings J, McArdle CS (1986) Studies on the in vivo disposition of Adriamycin in human tumours which exhibit different responses to the drug. Br J Cancer 53: 835–838Google Scholar
  3. 3.
    Dodion P, Egorin MJ, Engisch KL, Bachur NR (1985) Metabolism and disposition of menogaril (NSC 269148) in the rabbit. Cancer Res 45: 5352–5357Google Scholar
  4. 4.
    Egorin MJ, Van Echo DA, Whitacre MY, Forrest A, Sigman LM, Engisch KL, Aisner J (1986) Human pharmacokinetics, excretion, and metabolism of the anthracycline antibiotic menogaril (7-OMEN, NSC 269148) and their correlation with clinical toxicities. Cancer Res 46: 1513–1520Google Scholar
  5. 5.
    Eisenhauer EA, Pritchard KI, Perrault DJ, Verma S, Pater JL (1990) Activity of intravenous menogaril in patients with previously untreated metastatic breast cancer. A National Cancer Institute of Canada Clinical Trials Group study. Invest New Drugs 8: 283–287Google Scholar
  6. 6.
    Gregg RW, Molepo JM, Montpetit VJA, Mikhacl NZ, Redmond D, Gadia M, Stewart DJ (1992) Cisplatin neurotoxicity — the relationship between dosage, time, platinum concentration in neurological tissue and morphological evidence of toxicity. J Clin Oncol 10: 795–803Google Scholar
  7. 7.
    Long HJ, Powis G, Schutt AJ, Moertel CG (1987) Phase I and pharmacokinetic study of menogaril administered as a 72-hour continuous iv infusion. Cancer Treat Rep 71: 593–598Google Scholar
  8. 8.
    Mapleson W (1963) An electric analogue for uptake and exchange of inert gases and other agents. J Appl Physiol 18: 197–204Google Scholar
  9. 9.
    McGovern JP, Nelson KD, Lassus M, Cradock JD, Plowman J, Christopher JP (1984) Menogaril: a new anthracycline agent entering clinical trials. Invest New Drugs 2: 359–367Google Scholar
  10. 10.
    Peng YM, Alberts DS, Salmon SW, Davis TP (1984) A method for the simultaneous measurement of the anthracycline derivative 4′-deoxydoxorubicin and its metabolites by reversed phase liquid chromatography. Invest New Drugs 2: 227–280Google Scholar
  11. 11.
    Stewart DJ, Leavens M, Friedman J, Benjamin RS, Moore EC, Bodey GP, Valdivieso M, Burgess MA, Wiseman C, Loo T (1980) Penetration ofN-(phosphonacetyl)-L-aspartate into human central nervous system and intracerebral tumor. Cancer Res 40: 3163–3166Google Scholar
  12. 12.
    Stewart DJ, Benjamin RS, Luna M, Seifert WE, Loo TL (1982) Human tissue distribution of platinum aftercis-diamminedichloroplatinum. Cancer Chemother Pharmacol 10: 51–54Google Scholar
  13. 13.
    Stewart DJ, Lu K, Benjamin RS, Leavens M, Luna M, Yap HY, Loo TL (1983) Concentrations of vinblastine in human intracerebral tumor and other tissues. J Neurooncol 1: 139–144Google Scholar
  14. 14.
    Stewart DJ, Zhengang G, Lu K, Savaraj N, Feun LG, Benjamin RS, Keating MJ, Loo TL (1984) Human tissue distribution of 4′-(9-acridinylamino)-methanesulfon-m-aniside (NSC 14159, AMSA). Cancer Chemother Pharmacol 12: 116–119Google Scholar
  15. 15.
    Stewart DJ, Richard M, Hugenholtz H, Dennery J, Belanger R, Gerin-Lajoie J, Montpetit V, Nundy D, Prior J, Hopkins H (1984) Penetration of VP-16 (etoposide) into human intracerebral and extracerebral tumors. J Neurooncol 2: 133–139Google Scholar
  16. 16.
    Stewart DJ, Mikhael NZ, Nanji AA, Kacew S, Howard K, Hirte W, Maroun JA (1985) Renal and hepatic concentrations of platinum: relationship to cisplatin time, dose, and nephrotoxicity. J Clin Oncol 3: 1251–1256Google Scholar
  17. 17.
    Stewart DJ, Green RM, Mikhael NZ, Montpetit V, Thibault M, Maroun JA (1986) Human autopsy-tissue concentrations of mitoxantrone. Cancer Treat Rep 70: 1255–1261Google Scholar
  18. 18.
    Stewart DJ, Mikhael NZ, Nair RC, Kacew S, Montpetit V, Nanji A, Maroun JA, Howard K (1988) Platinum concentrations in human autopsy tumor samples. Am J Clin Oncol 11: 152–158Google Scholar
  19. 19.
    Stewart DJ, Maroun JA, Verma S, Perrault D, Earhart R (1989) Phase I study of weekly intravenous administration of menogaril to adults with solid tumors. Am J Clin Oncol 12: 511–518Google Scholar
  20. 20.
    Stewart DJ, Grewaal D, Green RM, Mikhael N, Montpetit V, Redmond D (1989) Adriamycin concentrations in human autopsy intracerebral and extracerebral tumors. J Neurooncol 7 [Suppl]: S27Google Scholar
  21. 21.
    Stewart DJ, Verma S, Maroun JA, Robillard L, Earhart RH (1990) Phase I study of oral menogaril administered on a once weekly schedule. Invest New Drugs 8: 43–52Google Scholar
  22. 22.
    Stewart DJ, Molepo JM, Green R, Hugenholtz H, Lamothe A, Redmond D, Montpetit V, Mikhael N (1990) Factors affecting tumor cisplatin levels. Proc Am Assoc Cancer Res 31: 180Google Scholar
  23. 23.
    Stewart D, Grewaal D, Green R, Redmond D (1991) Anthracycline levels in human autopsy heart tissue (abstract). Proc Am Assoc Cancer Res 32: 205Google Scholar
  24. 24.
    Stewart D, Eisenhauer E, Skillings J, Pritchard K, Buckman R, Vandenberg T, Verma S, Aitken S, Norris B (1992) Phase II study of oral menogaril as first line treatment for advanced breast cancer: a National Cancer Institute of Canada Clinical Trials Group study. Ann Oncol 3: 201–204Google Scholar
  25. 25.
    Stewart DJ, Aitken SE, Verma S, Maroun JA, Robillard L, Touchie M, Prosser IA, Earhart RH (1992) Phase I study of oral menogaril administered daily for 14 consecutive days. Ann Oncol 3: 401–403Google Scholar
  26. 26.
    Stewart DJ, Hugenholtz H, DaSilva V, Benoit B, Richard M, Verma S, Earhart R, Robillard L (1992) Phase II study of weekly intravenous menogaril in the treatment of recurrent astrocytomas in adults. J Neurooncol 13: 183–188Google Scholar
  27. 27.
    Zanette ML, Tirelli U, Sorio R, Zadro D, Figoli F, Monfardini S, D'Incalci M (1987) Pharmacokinetics of 7-con-O-methylnogarol in patients with solid tumors. Cancer Chemother Pharmacol 20: 67–70Google Scholar

Copyright information

© Springer-Verlag 1993

Authors and Affiliations

  • David J. Stewart
    • 1
    • 2
  • Darshan Grewaal
    • 1
    • 2
  • Robert M. Green
    • 1
  • Rakesh Goel
    • 1
    • 2
  • Nadia Mikhael
    • 2
  • Vital A. J. Montpetit
    • 2
  • Deidre Redmond
    • 1
  • Robert Earhart
    • 3
  1. 1.Ontario Cancer Treatment and Research FoundationOttawa Regional Cancer CentreOttawaCanada
  2. 2.University of Ottawa Faculty of MedicineOttawaCanada
  3. 3.Upjohn Pharmaceutical Co.KalamazooUSA

Personalised recommendations